---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-21-024319"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2021-12-01T23:59:59+00:00"
generated_at: "2026-06-28T04:24:24.348886+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# ChromaDex appoints Caroline S. Levy to Board, effective December 1, 2021

## Summary
- Caroline S. Levy, former Senior Equity Research Analyst at Macquarie Capital, joins ChromaDex Board.
- Ms. Levy appointed to Audit Committee and Nominating and Corporate Governance Committee.
- Annual retainer of $40,000, plus $10,000 (Audit) and $5,000 (Nominating) committee fees.
- Granted option to purchase 40,000 shares vesting over three years; annual meeting options of 20,000 shares.
- Board determined Ms. Levy is independent under Nasdaq rules.

## SEC filing metadata
- accession: 0001628280-21-024319
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2021-12-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000162828021024319/0001628280-21-024319-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000162828021024319/cdxc-20211201.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-21-024319
- JSON: https://secwatch.observer/filing/0001628280-21-024319.json
- Plain text: https://secwatch.observer/filing/0001628280-21-024319.txt

## Key facts
- Executive change
  Caroline S. Levy was appointed as Director at Niagen Bioscience, Inc..
  - Action: appointed
  - Role: Director
  source text: On December 1, 2021, the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company”) appointed Caroline S. Levy as a member of the Board effective on such date, to serve until the Company’s 2022 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1386570/000162828021024319/0001628280-21-024319-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.